Alnylam Pharmaceuticals Reports Q3 2026 Financial Results
Alnylam Pharmaceuticals announced its third-quarter 2026 financial results, reporting revenue of $1.46 billion and adjusted EPS of $16.26, while reaffirming its full-year 2026 financial outlook.